Nearly 75% of Americans are classified as overweight or obese. Addressing our nation's health crisis requires much more than ...

treatments such as Ozempic and Wegovy could even save lives, and efforts to make these treatments widely available are a welcome step. But it is essential that we recognize that this approach merely ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Alzheimer's, addiction, cardiovascular diseases, kidney disorders, sleep apnoea, diabetes, obesity, and overweight.

Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.

Ozempic and Wegovy, made by Novo, are on track to become the world’s top-selling drugs by 2025. Yet in 2024, ‘Wegovy Wednesday’ had already become one of the biggest weight-loss trends to sweep the ...

Elon Musk, 53, shared on Wednesday that he uses Mounjaro, a weight-loss medication, after previously endorsing similar drugs ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

In 1987, fewer than one in five American adults were obese, and by 1999, obesity was responsible for more than 300,000 excess ...

Two clinical trials investigating semaglutide (Ozempic, Wegovy) as an early Alzheimer's treatment are expected to wrap up in ...